BACKGROUND: Grade II and III meningiomas have higher rates of tumor recurrence than grade I meningiomas after surgery and/or external irradiation. As the utility of noninvasive treatments for brain tumors increases, it is becoming increasingly important to assess the likelihood that a tumor is not benign before treatment initiation. Hence, the authors have reviewed a large series of their patients to determine risk factors for higher-grade pathology, with particular interest paid to tumor location. METHODS: The authors reviewed 378 patients presenting at their institution from 2000 to 2007 with histologically confirmed meningioma, central pathology grading according to the World Health Organization 2000 guidelines, and tumor location confirmed with preoperative imaging. They performed univariate and multivariate logistic regression on potential risk factors for high-grade pathology. RESULTS: Risk factors for grade II/III pathology included nonskull base location (2-fold) and male sex (2-fold). Patients with prior surgery had a 3-fold increased incidence of higher-grade meningiomas at presentation at the authors' center. The authors controlled for this referral bias by performing a multivariate regression, and analysis without patients receiving prior treatment. Ninety-seven percent of operations were performed for tumor size and clinical symptoms, whereas <3% were performed for interval growth or features concerning higher-grade pathology. CONCLUSIONS: Nonskull-base meningiomas, male sex, and prior surgery impart increased risk for grade II or III pathology. This increased risk translates to probable poorer prognosis and increased likelihood of recurrence after treatment. Thus, it is prudent to take these specific variables into consideration in conjunction with the complete clinical presentation when advising patients regarding their prognosis.
BACKGROUND: Grade II and III meningiomas have higher rates of tumor recurrence than grade I meningiomas after surgery and/or external irradiation. As the utility of noninvasive treatments for brain tumors increases, it is becoming increasingly important to assess the likelihood that a tumor is not benign before treatment initiation. Hence, the authors have reviewed a large series of their patients to determine risk factors for higher-grade pathology, with particular interest paid to tumor location. METHODS: The authors reviewed 378 patients presenting at their institution from 2000 to 2007 with histologically confirmed meningioma, central pathology grading according to the World Health Organization 2000 guidelines, and tumor location confirmed with preoperative imaging. They performed univariate and multivariate logistic regression on potential risk factors for high-grade pathology. RESULTS: Risk factors for grade II/III pathology included nonskull base location (2-fold) and male sex (2-fold). Patients with prior surgery had a 3-fold increased incidence of higher-grade meningiomas at presentation at the authors' center. The authors controlled for this referral bias by performing a multivariate regression, and analysis without patients receiving prior treatment. Ninety-seven percent of operations were performed for tumor size and clinical symptoms, whereas <3% were performed for interval growth or features concerning higher-grade pathology. CONCLUSIONS: Nonskull-base meningiomas, male sex, and prior surgery impart increased risk for grade II or III pathology. This increased risk translates to probable poorer prognosis and increased likelihood of recurrence after treatment. Thus, it is prudent to take these specific variables into consideration in conjunction with the complete clinical presentation when advising patients regarding their prognosis.
Authors: Anne Durand; François Labrousse; Anne Jouvet; Luc Bauchet; Michel Kalamaridès; Philippe Menei; Robert Deruty; Jean Jacques Moreau; Michelle Fèvre-Montange; Jacques Guyotat Journal: J Neurooncol Date: 2009-06-27 Impact factor: 4.130
Authors: Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: David Pasquier; Stefan Bijmolt; Theo Veninga; Nicolas Rezvoy; Salvador Villa; Marco Krengli; Damien C Weber; Brigitta G Baumert; Emine Canyilmaz; Deniz Yalman; Ewa Szutowicz; Tzahala Tzuk-Shina; René O Mirimanoff Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-04 Impact factor: 7.038
Authors: Carl Wibom; Lina Mörén; Mads Aarhus; Per Morten Knappskog; Morten Lund-Johansen; Henrik Antti; A Tommy Bergenheim Journal: J Neurooncol Date: 2009-04-07 Impact factor: 4.130
Authors: Lewis A Rosenberg; Richard A Prayson; Joung Lee; Chandana Reddy; Samuel T Chao; Gene H Barnett; Michael A Vogelbaum; John H Suh Journal: Int J Radiat Oncol Biol Phys Date: 2009-06-01 Impact factor: 7.038
Authors: Nader Sanai; Michael E Sughrue; Gopal Shangari; Kenny Chung; Mitchel S Berger; Michael W McDermott Journal: J Neurosurg Date: 2010-05 Impact factor: 5.115
Authors: Douglas Kondziolka; David Mathieu; L Dade Lunsford; Juan J Martin; Ricky Madhok; Ajay Niranjan; John C Flickinger Journal: Neurosurgery Date: 2008-01 Impact factor: 4.654
Authors: Andreas Keller; Nicole Ludwig; Christina Backes; Bernd F M Romeike; Nicole Comtesse; Wolfram Henn; Wolf-Ingo Steudel; Christian Mawrin; Hans-Peter Lenhof; Eckart Meese Journal: Int J Cancer Date: 2009-01-15 Impact factor: 7.396
Authors: Onno Küster; Jens Schittenhelm; Oliver Schwartz; Richard Meyermann; Martin U Schuhmann Journal: Childs Nerv Syst Date: 2012-01-05 Impact factor: 1.475
Authors: Christopher S Graffeo; August R Dietrich; Bartosz Grobelny; Meng Zhang; Judith D Goldberg; John G Golfinos; Richard Lebowitz; David Kleinberg; Dimitris G Placantonakis Journal: Pituitary Date: 2014-08 Impact factor: 4.107
Authors: Pepijn van den Munckhof; Imke Christiaans; Susan B Kenter; Frank Baas; Theo J M Hulsebos Journal: Neurogenetics Date: 2011-10-26 Impact factor: 2.660
Authors: William L Hwang; Ariel E Marciscano; Andrzej Niemierko; Daniel W Kim; Anat O Stemmer-Rachamimov; William T Curry; Fred G Barker; Robert L Martuza; Jay S Loeffler; Kevin S Oh; Helen A Shih; Mykol Larvie Journal: Neuro Oncol Date: 2015-11-22 Impact factor: 12.300